site stats

Ikena therapeutics

WebDescription. Developer of an immuno-metabolism therapy technology designed to translate high-impact science into medicines for patients. The company's technology is meant for implementation in human clinical studies for non-oncology indications, enabling doctors to treat cancer patients in a better and hassle-free way. Web26 mrt. 2024 · Ikena Oncology, a company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, begins …

Ikena Oncology - Atlas Venture

WebFounded Date 2014. Founders Sofie Qiao. Operating Status Active. Last Funding Type Series C. Legal Name Vivace Therapeutics, Inc. Company Type For Profit. Contact Email [email protected]. Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel … psychology classical conditioning examples https://3dlights.net

Ikena Oncology Biomarker-Driven Cancer Therapeutics

Web7 okt. 2024 · Pioneering treatments for neurodegenerative diseases. Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders’ groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source. Atalanta's. branched siRNA. WebBackground. NTRK fusions are actionable biomarkers with efficient and well tolerated TRKis. Clinical profile and outcomes of pts with NTRK+ tumours receiving non-TRKi SoC are unknown and the prognosis of NTRK+ pts vs pts with NTRK fusion-negative (NTRK–) tumours is not well known. WebPatient-directed oncology therapies across pathways relevant in tumor and immune cells Ikena is a targeted oncology company focused on developing novel cancer therapies … host vmotion

Characteristics and outcomes of patients (pts) with NTRK fusion ...

Category:Pipeline Cedilla Therapeutics

Tags:Ikena therapeutics

Ikena therapeutics

Ikena Oncology to Present Preclinical Findings on IK-930, a

WebIkena Oncology (formerly Kyn Therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed therapies for cancer patients, by understanding what drives their disease. Ikena leverages core capabilities in oncology drug discovery, translational sciences and clinical development to build a next generation ... WebOur Pipeline. As we evolve with our science, our multifaceted approach builds a robust pipeline of patient direct therapies. At Ikena™, we are advancing a portfolio of targeted …

Ikena therapeutics

Did you know?

WebSpecialties Targeted Oncology, cancer therapeutics development, small molecule drug design, cancer biology, and translational science and biomarkers Locations Primary 645 … Web2 nov. 2024 · Ikena is developing IK-930 as a potential targeted therapy for patients with cancers that exhibit genetic alterations across the Hippo pathway. IK-930 is designed to selectively bind TEAD and to disrupt TEAD-dependent transcription of key genes involved in cancer progression, metastases, and therapeutic resistance.

Web24 mrt. 2024 · Ikena Oncology (formerly Kyn Therapeutics) is a biotechnology company that discovers and develops biomarker-driven therapies for cancer treatment. It develops … WebIkena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is …

Web21 uur geleden · Ikena Oncology. 8,517 followers. 1y. Our president and CEO Mark Manfredi, Ph.D., discussed Ikena’s unique corporate culture and goal to create a vibrant, innovative environment for employees to ... WebIkena is employing a robust, biomarker strategy by analyzing blood, tumor and urine biomarkers relevant to T cell checkpoint inhibitors and EP4 signaling. Ikena expects to …

WebIkena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product …

WebCedilla’s conditional inhibitors are small molecules that are unlocking historically undruggable cancer targets for therapeutic development. Our asset-by-asset approach is not one-size-fits-all. We start by developing a deep understanding of the disease biology and contextual biochemistry of the target. We then deploy cutting-edge ... psychology classes online for freeWebLearn about the team at Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal ... . Christopher’s Hospital in Philadelphia. Dr. Koehler serves as an independent director on the boards of directors of Ikena Therapeutics and Silverback Therapeutics. Dr. Koehler is a board-certified ... psychology classroom decorationsWeb3 dec. 2024 · Ikena is advancing five clinical, preclinical and discovery programs: IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading … host vpn at home